Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Covington
Johnson and Johnson
Harvard Business School
Argus Health
Dow
Novartis
Cipla
Fish and Richardson
Fuji

Generated: January 17, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,335,032

« Back to Dashboard

Summary for Patent: 6,335,032
Title: Orally administrable solid dosage form
Abstract:An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin is disclosed.
Inventor(s): Liebowitz; Stephen M. (Neshanic Station, NJ), Stupak; Elliot I. (West Caldwell, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Vadino; Winston A. (Whitehouse Station, NJ), Bowen; Frank E. (Rutherford, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:09/518,871
Patent Claims: 1. A rapidly dissolving ribavirin composition comprising ribavirin wherein the ribavirin is substantially free of another ribavirin polymorphic form and wherein more than about 80% by weight of the ribavirin dissolves in water in about 30 minutes.

2. An orally administrable solid ribavirin composition comprising ribavirin and a pharmaceutically acceptable disintegrant, wherein the ribavirin is substantially free of another ribavirin polymorphic form.

3. An orally administrable solid ribavirin composition having substantially uniform physical and chemical characteristics, said composition comprising ribavirin and a pharmaceutically acceptable disintegrant and wherein the ribavirin is substantially free of another ribavirin polymorphic form and wherein more than about 80% by weight of the ribavirin dissolves in water in about 30 minutes.

4. A rapidly dissolving ribavirin composition having a tap density of at least about 0.6 g/mL wherein the ribavirin is substantially free of another ribavirin polymorphic form.

5. The rapidly dissolving ribavirin composition of claim 4 wherein the tap density is in the range of about 0.75 to about 0.85 g/mL.

6. The rapidly dissolving ribavirin composition of claim 4 wherein more than about 80% by weight of the ribavirin dissolves in water in about 30 minutes.

7. The rapidly dissolving ribavirin composition of claim 4 which further comprises a pharmaceutically acceptable filler.

8. The rapidly dissolving ribavirin composition of claim 4 which further comprises a pharmaceutically acceptable disintegrant.

9. A rapidly dissolving ribavirin composition having a tap density of at least about 0.6 g/mL, wherein more than about 80% by weight of the ribavirin dissolves in water in about 30 minutes.

10. The rapidly dissolving ribavirin composition of claim 9 wherein the tap density is in the range of about 0.75 to about 0.85 g/mL.

11. The rapidly dissolving ribavirin composition of claim 9 wherein more than about 80% by weight of the ribavirin dissolves in water in about 30 minutes.

12. The rapidly dissolving ribavirin composition of claim 9 which further comprises a pharmaceutically acceptable filler.

13. The rapidly dissolving ribavirin composition of claim 9 which further comprises a pharmaceutically acceptable disintegrant.

14. The rapidly dissolving ribavirin composition of claim 1, wherein the disintegration time of the composition is less than about 10 minutes.

15. The rapidly dissolving ribavirin composition of claim 1 which further comprises a pharmaceutically acceptable filler.

16. The rapidly dissolving ribavirin composition of claim 1 which further comprises a pharmaceutically acceptable disintegrant.

17. The orally administrable solid ribavirin composition of claim 2, wherein the disintegration time of the composition is less than about 10 minutes.

18. The rapidly dissolving ribavirin composition of claim 2 which further comprises a pharmaceutically acceptable filler.

19. The orally administrable solid ribavirin composition of claim 3, wherein the disintegration time of the composition is less than about 10 minutes.

20. The rapidly dissolving ribavirin composition of claim 3 which further comprises a pharmaceutically acceptable filler.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
AstraZeneca
Chinese Patent Office
Covington
McKinsey
Cipla
Fuji
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot